To include your compound in the COVID-19 Resource Center, submit it here.

Daxas roflumilast: Additional Phase III data

Additional data from 2 double-blind, international Phase III trials (HERMES and AURA) showed that Daxas significantly improved mean pre-bronchodilator FEV1 by 48 mL vs. placebo (p<0.0001) and significantly reduced the rate of

Read the full 328 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE